SCHEMBL2092879

SCHEMBL2092879

[CH2]CCNc1ccc(C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.73
HTT P42858 3/20 0.47
HRH3 Q9Y5N1 1/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
POLB P06746 2/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
BLM P54132 1/20 0.44
PLEC Q15149 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092431 0.86 MAPT (0.67) MAPTHTTHRH3MEN1KMT2A
SCHEMBL2065837 0.85 MAPT (1.00) MAPTHTTHRH3MEN1KMT2A
SCHEMBL2088459 0.85 MAPT (0.64) MAPTHTTHRH3MEN1KMT2A
SCHEMBL2093052 0.83 MAPT (0.61) MAPTHTTHRH3MEN1KMT2A
SCHEMBL5077122 0.83 MAPT (0.61) MAPTHTTHRH3MEN1KMT2A
Hydrochloric Acid SCHEMBL15329323 0.82 MAPT (0.94) MAPTHTTHRH3MEN1KMT2A
SCHEMBL1453806 0.80 MAPT (0.64) MAPTHTTMEN1KMT2AALDH1A1
SCHEMBL11518048 0.80 MAPT (0.80) MAPTHTTHRH3MEN1KMT2A
SCHEMBL11520411 0.78 MAPT (0.85) MAPTHTTHRH3MEN1KMT2A
SCHEMBL409332 0.78 MAPT (0.76) MAPTHTTHRH3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1662527-A Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors ALMIRALL PRODESFARMA SA (CH) 2005-08-31 CN claimed
CN-101445469-B Inhibitors of histone deacetylase METHYLGENE INC 2013-02-13 CN disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
CN-101805309-A Benzamide derivatives as histone deacetylase inhibitors ASTRAZENECA AB 2010-08-18 CN disclosed
CN-100548978-C Pyrrolidinium derivatives as M3 muscarinic receptor antagonists ALMIRALL PRODESFARMA SA (ES) 2009-10-14 CN disclosed
CN-100497345-C 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2009-06-10 CN disclosed
CN-101445469-A Inhibitors of histone deacetylase METHYLGENE INC (CA) 2009-06-03 CN disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1221440-B1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators OTSUKA PHARMA CO LTD (JP) 2007-04-25 EP disclosed
EP-0725316-B1 Electrophotographic photoreceptor KONISHIROKU PHOTO IND (JP) 1999-06-30 EP disclosed
US-5846679-A Electrophotographic photoreceptor KONICA CORPORATION (JP) 1998-12-08 US disclosed
US-5800956-A Electrophotographic photoreceptor with specific interlayer KONICA CORPORATION (JP) 1998-09-01 US disclosed
EP-0671663-B1 Electrophotographic photoreceptor KONISHIROKU PHOTO IND (JP) 1998-08-12 EP disclosed
US-5716745-A INTERLAYER COMPRISE AN ALKOXY METALLIC CHELATE COMPOUNDS OF TITANIUM OR ALUMINUM HAVING A CHELATE GROUP OF ACETOACETIC ESTER OR DIKETONE AND AN ORGANOSILANE COMPOUND HAVING AT END A METHACRYLOXY OR AMINO GROUP; EXPOSURE, REVERSE DEVELOPMENT KONICA CORPORATION (JP) 1998-02-10 US disclosed
EP-0765314-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-02 EP disclosed
EP-0763782-A1 Electrophotographic photoreceptor KONICA CORPORATION (JP) 1997-03-19 EP disclosed
EP-0725316-A1 Electrophotographic photoreceptor KONICA CORPORATION (JP) 1996-08-07 EP disclosed
WO-1995034540-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-12-21 WO disclosed
EP-0671663-A1 Electrophotographic photoreceptor KONICA CORPORATION (JP) 1995-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MAPT 4299/4885HTT 4689/4885HRH3 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.